Back
PTCT logo

PTC Therapeutics Inc (PTCT)

Biotechnology
PTCT · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →
$84.83
−5.17%
Price · 1 year
Loading live analysis…
Loading analysis…

Intrinsic Investor is for education and research only — not financial advice.

Key metrics

EPS
$7.73
ROE
Gross margin
38.3%
Debt/Equity
Revenue growth
-76.8%
P/B ratio
Beta
Forward P/E

PTC Therapeutics Inc — company intelligence

Earnings surprises

Q1 2026$-0.03 vs $-0.48 est+93.7%
Q4 2025$-1.67 vs $0.04 est-4460.3%
Q3 2025$0.20 vs $-1.40 est+114.3%
Q2 2025$-0.83 vs $-1.08 est+23.3%

Analyst consensus · 21 analysts

17 Buy3 Hold1 Sell
Updated Jul 10, 2026

Insider activity · 90 days

1 buy23 sellsnet -85,622 shares
Almstead Neil Gregoryother 19,859 · Jun 25, 2026
Almstead Neil GregorySell 419 · Jun 25, 2026
Almstead Neil GregorySell 582 · Jun 25, 2026

AI Valuation Narrative

Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.

Weekly undervalued picks (like PTCT)

Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.

Free. No spam. We only email once per week.

Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.